Organoids Market Size, Trends & Competition Analysis

Organoids Market Size,Trends and Future Growth

The global organoids market was estimated at US$ 59 million in 2023 and is projected to grow to US$ 381.7 million by 2034, rising at a compound annual growth rate (CAGR) of 18.5% from 2024 to 2034. Organoids are in high demand because they can replicate the in vivo environment of human organs or the body up to a certain extent, which helps in better analysis and understanding of therapeutic drugs, therapies, disease analysis, and others.

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

Organoids are simplified and miniaturized organs produced in vitro using scaffolds to mimic the structural function and biological complexity of an organ. Different cells, such as pluripotent stem cells, embryonic cells, tissue, and adult stem cells, are in growing organoids. The organoids market is a composition of products, equipment, research facilities, research and development, and other things that are needed or used in developing and studying organoids. The market’s demand is high due to the application of organoids. Researchers use it in studying the cell cycle, testing new therapeutic drugs, animal development, the function of cells, cell-cell interactions, and many more things that can be used in the future for evidence-based research and healthcare.

Organoids Market Trends

• In May 2024, Sinai Health announced a $10 million financing to support the production of lab-grown organoids for medication development and disease research. Sinai Health will establish a cutting-edge tissue engineering platform to facilitate the production of organoids such as the brain, gut, lung, and kidney.
• In March 2024, an organoid resource center at USC is to be funded by a $3.95 million CIRM award. The USC ASCEND Center will be established under the grant to provide stem cell-derived organ models to all grantees and recipients of award announcements.
• In November 2023, the € 4.5 million Pre-Series A financing led by i&i Biotech Fund, Invest AG, aws Gründungsfonds II, and Tensor Ventures was closed, according to HeartBeat.bio AG is a biotech firm developing a highly scalable human organoid and AI-supported drug development platform for heart disease.
• In November 2023, Vivodyne, a biotech company that tests pharmaceuticals on lab-grown human organs to find and develop more effective ones, announced the closing of a $38 million seed fundraising round headed by Khosla Ventures.

Organoids Can Completely Stop Animal Abuse in the Future

Animal testing is a very common practice in healthcare. Drug effects, genetic variation, new procedures, genetic mutations, and all aspects associated with human health are tested on animals before clinical trials are conducted on humans. However, a lot of activists, along with PETA, are against this practice and consider it animal abuse. Many governments are also taking initiatives to stop the use of animal models. In other industries, like makeup, the use of animal models is being banned. However, it will take time to ban animal models in the healthcare industry due to their importance in human safety. With growing R&D in developing more accurate organoids, the use of animal models for testing can be completely mitigated in the future. With highly accurate organoids, the results will be more accurate and useful.

Challenge: Organoids are not Highly Advanced

The organoids market faces challenges because the organoids that are now being developed are not highly accurate in comparison to real organs. Due to this, the results achieved using these organoids are not accurate; apart from this, better technology is needed to mimic the real organs, which is, again, a very challenging task.

Regional Insights

North America Dominated the organoids market in 2023. The region is growing due to growing research and development associated with organoids and spheroids. The region has advanced infrastructure and technology that provide an advantage to researchers conducting organoids-based research. Countries like the U.S. and Canada majorly contribute to the market’s growth.

The U.S. held the largest share of the organoids market in 2023 due to growing research in oncology and stem cells. The researchers and citizens of the U.S. are highly invested in precision medicine and cancer therapies due to the growing number of cancer patients and rare diseases. The U.S. has institutions like the FDA, National Cancer Institute, National Science Foundation, and others that are significantly contributing to the organoids market.

For instance,

• In August 2024, US$ 14 million has been allocated by the U.S. National Science Foundation to seven multidisciplinary research projects under the Emerging Frontiers in Research and Innovation (EFRI): Biocomputing via EnGINeering Organoid Intelligence initiative. In addition to increasing engagement in biocomputing research, this financing promotes basic and morally sound research and development of organoid intelligence systems.

Asia Pacific is expected to grow at the fastest rate during the forecast period.

A strong biotechnology and healthcare industry, along with substantial government backing for research and development, have put nations like South Korea, China, and Japan at the forefront of organoid research and application in the Asia Pacific region. The enormous medication manufacturing, increased emphasis on biopharmaceutical R&D, and rise in cancer occurrence in this area all contribute to the organoids market's expansion.

Regarding promoting market expansion, the Indian government is heading in the correct direction. An attempt has been made to replace the use of animals in research, particularly drug testing, with an amendment to the New Drugs and Clinical Trial Rules (2023) that the Indian government adopted in July 2023. The modification allows researchers to replace human-relevant and non-animal methods, including as 3D organoids, organs-on-chip, and advanced computational tools, for assessing the safety and efficacy of new drugs.

Segmental Insights

By type, the stem cell source dominated the organoids market in 2023. The three-dimensional organoid culture created from stem cells has offered new options for regenerative medicine and transplantation. To obtain a more individualized medicine, researchers have merged organoids with tissue engineering technologies to enhance reproducibility, precision in constitution and throughput, and genetic correction.

By type, the tumor cell source is expected to grow at the fastest rate during the forecast period. Tumor organoids may be created in vitro by cultivating tumor cells in malignant effusions, and they can be utilized for medication sensitivity studies in addition to in situ malignancies.

For instance,

• In February 2024, In the first trial headed by WEHI, scientists developed tumors in the lab to precisely forecast which medications would be effective for patients with colon cancer — even before they start therapy. Organoid drug testing can 90% accurately predict how patients with advanced colon cancer would respond to therapy, according to a WEHI-led research.

By application, the pharmaceutical R&D segment held the largest share of the organoids market in 2023. Pharmaceutical companies use organoids to their full potential. During R&D, pharma companies use organoids to test new drugs or therapeutic products and check their accuracy. It prevents the use of animal models and provides better results. The companies continuously conduct R&D due to the growing demand for therapeutics in the market.

By application, the precision medicine segment is expected to achieve the fastest CAGR during 2024-2034. The application of precise and dependable in vitro and in vivo disease models is an increasingly popular topic of focus in precision medicine. These model systems offer a platform for testing and developing targeted therapeutic medicines in addition to offering insightful information about disease processes and pathology.

Recent Developments in the Organoids Market

• In June 2024, in Cardiff, UK, Molecular Devices, LLC formally launched its purpose-built location. The multimillion-pound facility was specially designed to accommodate the business's exclusive bioprocess workflow and innovative bioreactor technology, which allow for the large-scale, quality-controlled production of patient-derived organoids (PDOs).
• In February 2024, the world's leading biological materials management and standards organization, ATCC, and Tissue Dynamics, a cutting-edge pharma-tech startup that combines sophisticated AI tools with bionic human organoids, have partnered to create cardiac organoids-based workflow-friendly kits that will enhance cardiac safety testing for drug development.

Top Companies in the Organoids Market

• Hub Organoids 
• Definigen
• Cellesce Ltd.
• Thermo Fisher
• Sanofi
• NeyroblastGX
• StemCell Technologies
• Organoid Therapeutics
• Bio-Techne
• Thermo Fisher Scientific Inc.
• 3Dnamics Inc.
• PeproTech Inc.
• Molecular Devices, LLC
• Merck KGaA
• Corning Inc.
• CN Bio Innovations Ltd.

Segments Covered in the Report

By Type

• Stem Cell Source
• Tumor Cell Source

By Application

• Pharmaceutical R & D
• Precision Medicine
• Academic & Research Institute

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
• • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait